Market Size of Gemcitabine Hydrochloride Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 7.10 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gemcitabine Hydrochloride Market Analysis
The Gemcitabine Hydrochloride Market is expected to register a CAGR of 7.1% during the forecast period.
COVID-19 pandemic had a substantial impact on patients with underlying diseases; gemcitabine was shown to have both anti-cancer and anti-viral activity. For instance, the NCBI article published in February 2021 suggested that gemcitabine's difluoro group is essential for the antiviral action and its combination with other antiviral medications that have been studied, including remdesivir, may be a desired alternative for treating SARS-CoV-2 infection. Thus, such potential benefits of gemcitabine had a notable impact on the demand for gemcitabine hydrochloride, ultimately impacting the market growth during the pandemic period. In addition, the demand for gemcitabine is expected to remain intact during the post-pandemic period, thereby contributing to the market's growth over the forecast period.
The gemcitabine hydrochloride market is expected to grow during the forecast period due to the significantly increased prevalence of cancer prevalence globally owing to the rising usage of gemcitabine with other drugs in the treatment of cancer. Further, increased awareness about cancer and patient support programs are among the major factors driving the growth of the studied market. According to the World Health Organization factsheet published in February 2022, in 2021, an estimated 1.9 million new cancer cases were diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children develop cancer globally. Cervical cancer is the most common in 23 countries, such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon and rectum, and prostate cancers. Thus, the high burden of cases of cancer is generating the demand for effective treatment options such as gemcitabine owing to the potential usage with other drugs in the treatment of cancer, thereby contributing to the growth of the market over the forecast period.
Additionally, the increasing product developments by key market players and product approvals are expected to contribute to the market's growth. For instance, in September 2022, Syros Pharmaceuticals received FDA orphan drug designation for the product SY-5609, a CDK7 inhibitor, in combination with chemotherapy for patients with relapsed metastatic pancreatic cancer. The clinical initiated regarding the product, the participants are assigned to SY-5609 plus gemcitabine at approved doses. Therefore, owing to the aforementioned factors, such as rising cancer cases, increasing demand for effective therapeutics, along with increasing product developments, the studied market is anticipated to witness growth over the analysis period. However, the stringent regulatory framework is likely to impede the market growth.
Gemcitabine Hydrochloride Industry Segmentation
As per the scope of the market, gemcitabine hydrochloride is the antimetabolite-antineoplastic agent with synthetic pyrimidine nucleoside. It can be used with other oncology agents in combination, such as paclitaxel, cisplatin, and others.
The Gemcitabine Hydrochloride Market is segmented By Product Type (Injection, Solution), By Indication (Breast Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Others), and by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for the above segments.
By Product Type | |
Injection | |
Solution |
By Indication | |
Breast Cancer | |
Non-small Cell Lung Cancer | |
Pancreatic Cancer | |
Others |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gemcitabine Hydrochloride Market Size Summary
The gemcitabine hydrochloride market is poised for significant growth, driven by the increasing global prevalence of cancer and the rising demand for effective treatment options. The market's expansion is further supported by the drug's dual anti-cancer and anti-viral properties, which gained attention during the COVID-19 pandemic. This period saw a notable increase in demand for gemcitabine hydrochloride, as it was explored for potential use in treating SARS-CoV-2 infections. The post-pandemic period is expected to maintain this demand, contributing to the market's upward trajectory. Key factors such as heightened awareness of cancer, patient support programs, and the drug's combination with other therapeutics are also fueling market growth. Additionally, ongoing product developments and regulatory approvals by major market players are anticipated to bolster the market's expansion over the forecast period.
The lung cancer segment is expected to play a pivotal role in the market's growth, driven by the high prevalence of lung cancer cases and the demand for effective treatments. Research studies highlighting the efficacy of gemcitabine in lung cancer treatment, particularly in combination with platinum agents, are expected to further propel this segment. North America is projected to hold a significant share of the market, attributed to the region's high cancer incidence and advancements in product offerings. The availability of low-cost generic options and strategic reformulations are additional factors supporting market growth in this region. The market is characterized by fragmentation, with several major players such as Eli Lilly & Co., Pfizer Inc., and Mylan Pharmaceuticals Inc. dominating the landscape. Ongoing clinical trials and new treatment developments are expected to continue driving market growth, despite challenges posed by stringent regulatory frameworks.
Gemcitabine Hydrochloride Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Burden of Cancer
-
1.2.2 Increasing Research & Development Activities
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Framework
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product Type
-
2.1.1 Injection
-
2.1.2 Solution
-
-
2.2 By Indication
-
2.2.1 Breast Cancer
-
2.2.2 Non-small Cell Lung Cancer
-
2.2.3 Pancreatic Cancer
-
2.2.4 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Gemcitabine Hydrochloride Market Size FAQs
What is the current Gemcitabine Hydrochloride Market size?
The Gemcitabine Hydrochloride Market is projected to register a CAGR of 7.10% during the forecast period (2024-2029)
Who are the key players in Gemcitabine Hydrochloride Market?
Eli Lilly & Co. , Apotex Inc. , Fressenius Kabi USA, Mylan Pharmaceuticals Inc. and Pfizer Inc. (Hospira Inc.) are the major companies operating in the Gemcitabine Hydrochloride Market.